PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases

• Published in: Journal of thrombosis and thrombolysis Vol. 51; no. 1; pp. 89 - 95
• Main Authors: Ansari, Narges, Najafi, Sahar, Shahrabi, Saied, Saki, Najmaldin
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.01.2021; Springer Nature B.V
• Subjects: Cardiology; Cardiovascular diseases; Genetic screening; Hematology; Hemostasis; Homeostasis; Medicine; Medicine & Public Health; Platelet aggregation; Risk factors; Platelet aggregation; Cardiovascular diseases; PEAR1; Hemostasis; Polymorphism
• ISSN: 0929-5305; 1573-742X; 1573-742X
• DOI: 10.1007/s11239-020-02149-w

Platelet Endothelial Aggregation Receptor (PEAR1), as a platelet receptor, plays a vital role in hemostasis. This receptor, by its extracellular part, causes platelet adhesion and consequently initiates platelet aggregation. Dysfunction of PEAR1 can disrupt platelet aggregation in patients with cardiovascular diseases (CVDs). The content used in this paper has been taken from English language articles (2005–2020) retrieved from Pubmed database and Google scholar search engine using “Cardiovascular Disease”, “PEAR1”, “Polymorphism”, and “Platelet Aggregation” keywords. Some PEAR1 polymorphisms can disrupt homeostasis and interfere with the function mechanism of cardiac drugs. Since polymorphisms in this gene affect platelet function and the platelet aggregation process, PEAR1 could be further studied in the future as an essential factor in controlling the treatment process of patients with cardiovascular diseases. PEAR1 polymorphisms through disruption of the platelet aggregation process can be a risk factor in patients with CVDs. Therefore, controlling patients through genetic testing and the evaluation of PEAR1 polymorphisms can help improve the treatment process of patients. According to the studies on the PEAR1 gene and the effect of different polymorphisms on some crucial issues in CVDs patients (changes in platelet activity), it is clear that if there is a significant relationship between polymorphisms and CVDs, they can be used as prognostic and diagnostic markers. This study aims to evaluate the prognosis and drug treatment of the PEAR1 gene in CVDs patients.